Jim Woodgett, Ph.D., moved to Canada from the UK in 1992 to work at the Ontario Cancer Institute. His biomedical research there focused on the signalling mechanisms that underscore malignant growth, degenerative diseases and diabetes. From 1995-2005, he was an International Scholar of the Howard Hughes Medical Institute and in 1997 was appointed Head of the Division of Experimental Therapeutics, where he held the Amgen Chair of Cancer Biology. He has been an MRC Scientist and CIHR Senior Scientist and is known internationally for his work on a class of proteins that regulate cellular processes, termed protein kinases. Dr. Woodgett has been internationally recognized for his co-discoveries of the molecules PKB/Akt and SAPK/JNKs, which have central roles in the evolution of cancer. He is also an authority on the functions of the GSK-3 genes, which play significant roles in insulin/diabetes and brain development/Alzheimers disease, as well as bipolar disorder. In 2005 he was appointed as the fourth Director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital where he has developed disease models for diabetes and breast cancer and identified mechanisms that maintain the pluripotentiality of stem cells. He is an elected fellow of the Royal Society of Canada and holds the Koffler Chair at Sinai Health System.